Alnylam Pharma

Alnylam Pharmaceuticals surged ~4.9% to $316.49 during regular trading, fueled by pre-market gains over 12% after announcing a 3-year strategic AI drug discovery collaboration with Inceptive Nucleics, alongside multiple analyst reaffirmations of Buy ratings (Barclays, HC Wainwright). Q1 revenue soared 96% YoY to $1.167B, net profit jumped over 12x to $206M, and ROE hit 88%, underscoring fundamental momentum. However, the stock still trades 36% below its 52-week high of $495.55, with a YTD decline of ~21%, though today's strong volume pushed price above its MA20 ($292.82) and MA60 ($300.34). Post-market quotes fell back to $302, suggesting near-term uncertainty remains.